Foundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy Assay
The FoundationACT assay is designed to identify clinically-relevant genomic alterations driving the growth of a patient's cancer. This liquid biopsy assay can help physicians identify treatment options by providing clinically actionable information about potential targeted therapies and/or available clinical trials from only a blood sample. FoundationACT is analytically validated to detect genomic alterations in more than 60 of the most clinically-relevant cancer genes in solid tumors.
"We believe
About
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the performance of FoundationACT; the benefits of comprehensive genomic profiling in cancer care; and the ability of NYS physicians to continue to utilize FoundationACT. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that FoundationACT will not identify genomic alterations in the same manner as prior analyses;
View source version on businesswire.com: http://www.businesswire.com/news/home/20171002005201/en/
Media Contact:
pr@foundationmedicine.com
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media